» Articles » PMID: 10988101

Trends in Pulmonary Function in Patients with Cystic Fibrosis Correlate with the Degree of Glucose Intolerance at Baseline

Overview
Specialty Critical Care
Date 2000 Sep 16
PMID 10988101
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with cystic fibrosis, CF-related diabetes mellitus (CFRD) has been associated with increased morbidity and mortality. Whether glucose intolerance is also associated with poor outcomes is unclear. To better define these relationships we prospectively followed a group of 152 patients with CF without diabetes for 4 yr. Patients were classified as having normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or CFRD without fasting hyperglycemia (CFRD-No FH). FEV(1), FVC, and body mass index (BMI) were measured at baseline and quarterly. At baseline 45% of the patients had NGT, 38.8% had IGT, and 15.8% had CFRD-No FH. FEV(1), FVC, and BMI at baseline were comparable among these groups (all p > 0.1). After 4 yr an overall decline in FEV(1) and FVC occurred, with no change in BMI. The rates of decline for FEV(1) and FVC correlated with the glucose tolerance groups, with the highest rates of decline occurring among the CFRD-No FH group. In addition, patients in the lowest quartile for insulin production at baseline experienced the highest rates of pulmonary function decline over time, suggesting a relationship between insulin deficiency and clinical deterioration. We conclude that the degree of glucose intolerance is a strong determinant of future lung function decline in patients with CF.

Citing Articles

Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis.

Uzunoglu B, Selcuk Balci M, Kalyoncu M, Karabulut S, Metin Cakar N, Yildiz C Pediatr Pulmonol. 2025; 60(3):e71037.

PMID: 40062574 PMC: 11892081. DOI: 10.1002/ppul.71037.


Exogenous insulin does not reduce protein catabolism in pre-diabetic cystic fibrosis patients: A randomized clinical trial.

Schiavon M, Cobelli C, Nair K, Klaus K, Toffolo G, Zhang L J Cyst Fibros. 2024; 24(1):57-65.

PMID: 39516143 PMC: 11788023. DOI: 10.1016/j.jcf.2024.10.005.


Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis.

Bestas A, Unal E, Aktar Karakaya A, Beyazit N, Savas S, Sen V Sisli Etfal Hastan Tıp Bul. 2024; 58(3):389-394.

PMID: 39411039 PMC: 11472201. DOI: 10.14744/SEMB.2024.65983.


Advances in diabetes technology to improve the lives of people with cystic fibrosis.

Scully K, Marks B, Putman M Diabetologia. 2024; 67(10):2143-2153.

PMID: 38995399 DOI: 10.1007/s00125-024-06223-3.


Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.

Scully K, Brenner L, Martin K, Ruazol M, Sawicki G, Uluer A Front Endocrinol (Lausanne). 2024; 15:1293709.

PMID: 38379863 PMC: 10876871. DOI: 10.3389/fendo.2024.1293709.